

**INTERNATIONAL INVASIVE LOBULAR BREAST CANCER (ILC) SYMPOSIUM 2023
PITTSBURGH, PA – SEPTEMBER 28-30, 2023**

THURSDAY, SEPTEMBER 28TH

7:30am	Registration and Breakfast
8:30am-11:30am	<p>Workshop: ILC Basics</p> <ul style="list-style-type: none"> • Basic Science and Biology of ILC • Clinical Considerations of ILC • Progress in Patient Advocacy • Metastatic ILC • Myth-buster • Communication and SM
11:30am	Lunch
12:30pm	<p>Introduction to International Invasive Lobular Breast Cancer Symposium 2023 Steffi Oesterreich, PhD (UPMC Hillman Cancer Center, Pittsburgh, PA)</p>
12:40pm	<p>Keynote: Stuart Schnitt, MD (Dana-Farber Cancer Institute, Boston, MA) – The Leigh Pate Memorial Lectureship on Lobular Breast Cancer” <i>TBD</i></p> <p>Introduction by: Flora Migyanka (Breast Cancer Advocate, Dynami), and Anne Vincent-Salomon, MD, PhD (Institut Curie, Paris, France)</p>
1:30pm	<p>Session 1: Pathology, Diagnosis, ILC Variants and Lobular Neoplasia Chair: Rohit Bhargava, MD (UPMC Magee-Womens Hospital, Pittsburgh, PA)</p>
	<p>Jorge Reis-Filho, MD, PhD (Memorial Sloan Kettering Cancer Center, NYC, NY) <i>TBD</i></p>
	<p>Maxim De Schepper, MD, PhD (KU Leuven, Belgium) <i>Homogenization of Pathological Diagnosis of ILC</i></p>
	<p>Tari King, MD (Dana-Farber Cancer Institute, Boston, MA) <i>TBD (LCIS)</i></p>
	TBD
2:50pm	Coffee Break
3:20pm	<p>Session 2: E-cadherin and the Tumor Microenvironment Chair: Rebecca Riggins, PhD (Georgetown University, Washington, DC)</p>
	<p>Patrick Derksen, PhD (UMC Utrecht, Netherlands) <i>TBD</i></p>
	<p>Val Brunton, PhD (University of Edinburgh Scotland) <i>Cancer-Associated Fibroblasts in the ILC Microenvironment</i></p>
	TBD

4:20pm	Special Session: Signaling by Adhesion and Growth Factor Receptors. Their Role in ILC Biology and Treatment Chair: Patrick Derksen (UMC Utrecht, Netherlands)
	Special Lecture Yossi Yarden, PhD (Dwek Institute for Cancer Therapy Research, Rehovot, Israel) <i>TBD (GFR)</i>
	Thijs Koorman, PhD (UMC Utrecht, Netherlands) <i>Targeting Survival Cues to Treat Lobular Breast Cancer</i>
	Arielle Hanker, PhD (University of Texas Southwestern, Dallas, TX) <i>Therapeutic Targeting of HER2 Drive Mutations in ILC</i>
	Rinath Jeselsohn, MD (Dana-Farber Cancer Institute, Boston, MA) <i>TBD (endocrine resistance)</i>
	Otto Metzger, MD (Dana-Farber Cancer Institute, Boston, MA) <i>TBD (therapeutic approaches targeting GFR signaling)</i>
6:30pm	Poster Session (wine and cheese served)
7:30pm	Dinner and Entertainment - TBD

FRIDAY, SEPTEMBER 29TH

7:00am	Yoga (optional)
7:45am	Breakfast
8:30am	Keynote: Cathrin Brisken, MD, PhD (Swiss Federal Institute of Technology Lausanne, Switzerland, The Institute of Cancer Research, London, UK) Introduction by: Leonie Young, PhD (RCSI, Dublin, Ireland)
9:15am	Session 3: Modeling ILC Chair: Sean Egan, PhD (University of Toronto, Canada)
	Adrian Lee, PhD (UPMC Hillman Cancer Center, Institute for Precision Medicine, Pittsburgh, PA) <i>TBD (ILC Modeling)</i>
	Damir Vareslija, PhD (Royal College of Surgeons, Dublin, Ireland) <i>Exploring New Targets: Molecular Profiling of Metastatic Patient-Derived Models</i>
	TBD
10:15am	Coffee
10.35am	How Researchers, Clinicians and Patient Advocates Can Accelerate Lobular Breast Cancer Research – In Memory of Leigh Pate
	Steffi Oesterreich, PhD (University of Pittsburgh, UPMC Hillman Cancer Center) <i>TBD</i>
	Matt Sikora, PhD (University of Colorado Denver, Anschutz Medical Campus, Denver, CO)

	<i>Building Bridges in Research Outreach and Lobular Cancer Biology</i>
	Lori Petitti (Independent ILC Advocate) <i>TBD</i>
	Claire Turner (Lobular Breast Cancer, UK) <i>TBD</i>
	Siobhan Freaney (Lobular Ireland) <i>'Sowing the seeds of Change' - Leigh's Legacy.</i>
	Flora Migyanka (Independent Advocate/Founder, Dynami Foundation) <i>TBD</i>
	Jagmohan Hooda, PhD (UPMC Hillman Cancer Center, Pittsburgh, PA) (TBD, BCRF) <i>BCRF ILC Legacy Project – Lobular Breast Cancer Biobank</i>
	TBD (Susan G. Komen)
12.00pm	Lunch and Poster Session
1.30pm	Panel Discussion – Diversity, Equity, Inclusion, Justice (DEIJ) Aspects in ILC Research, Treatment and Advocacy Chair: Stephanie Walker (MBCI Advocate, MBC Alliance-Become Project) Advisors: Julia Maues (Breast Cancer Advocate, GRASP)
2.30pm	Session 4: Unique Imaging Modalities in ILC Chair: Vincent Vandecaveye, MD, PhD (KU Leuven, Belgium)
	Amy Clark, MD, MSCE (Penn Medicine, University of Pennsylvania, Philadelphia) <i>TBD</i>
	Matthew Covington, MD (University of Utah, Salt Lake City) <i>Challenges and Potential Solutions for Imaging of Invasive Lobular Carcinoma</i>
	Hannah Linden, MD, FACP (Fred Hutch Cancer Center, University of Washington, Seattle) <i>TBD</i>
	Gary Ulaner, MD (Hoag Family Cancer Institute, University of Southern California, Irvine) <i>Estrogen Receptor (ER)-targeted PET: Clinical Applications and Interpretation</i>
	Vincent Vandecaveye, MD, PhD (Katholieke Universiteit Leuven, Belgium) <i>Whole Body Diffusion-Weighted MRI in Lobular Breast Cancer: Development and Clinical Applications for Staging and Response Assessment</i>
4.00pm	Coffee
4.30pm	Session 5: Genetics of ILC –Use of clinical specimens and data Chair: Elinor Sawyer (Kings College, London, UK)
	Giovanni Corso, MD, PhD (European Institute of Oncology, University of Milan, Italy) <i>Impact of germline CDH1 variants in hereditary lobular breast cancer predisposition</i>
	Ethan Sokol, PhD (Foundation Medicine, Boston, MA) <i>Identification of Targetable Vulnerabilities in ILC Using Comprehensive Genomics Profiling</i>

	Maria Margarete Karsten, MD, PhD (Charité-Universitätsmedizin Berlin, Germany) <i>IDA – How an Individualized Digital Aid for ILC Can Assist Patients and Research</i>
5:30pm	Session 6: Challenges in Treatment of ILC Chair: Gorantla, Vikram (UPMC, Pittsburgh)
	Jason Mouabbi, MD (University of Texas, MD Anderson Cancer Center, Houston) <i>TBD (CDK4/6 and more)</i>
	Julia Foldi, MD, PhD (University of Pittsburgh, UPMC, Pittsburgh, PA) <i>Chemotherapy response in patients with ILC</i>
	TBD
6:30pm	Dinner, Entertainment and Potential Sessions - TBD

SATURDAY, SEPTEMBER 30TH

7:30AM	Round Table/Hot topics Discussions Over Breakfast
9:00AM	Session 7: Local Treatment of ILC Chair: TBD
	Priscilla McAuliffe, MD, PhD (UPMC Magee-Womens Hospital and UPMC Hillman Cancer Center, Pittsburgh, PA) <i>TBD</i>
	Rita Mukhtar, MD (UCSF, San Francisco, CA) <i>TBD</i>
	TBD
10:00am	Session 8: Treatment Resistance and Metastases Chair: Britta Weigelt, PhD (Memorial Sloan Kettering Cancer Center, NYC, NY)
	Massimo Cristofanilli, MD (Sandra Edward Meyer Cancer Center, Weill Cornell, NYC, NY) <i>TBD (liquid biopsies)</i>
	Peter Simpson, MD (University of Queensland, Australia) <i>TBD (Unique metastases, and LobSig)</i>
	Karen Van Baelen, MD (KU Leuven, Belgium) <i>Metastatic Spread in Patients with Mixed ILC/NST: Results from Post-Mortem Tissue Donation Programs</i>
11:00pm	Coffee Break
11:30am	Case Reports Chair: Nancy Davidson, MD (Fred Hutch Cancer Center, Seattle, WA) Presenters: Rachel Jankowitz, MD (University of Pennsylvania, Philadelphia), Kit Lu, MD (UPMC, Harrisburg, PA) Elinor Sawyer (Kings College London, UK), Dhaval Mahtal, MD (UPMC, Monroeville, PA) and Chuck Geyer, MD (NSABP, Pittsburgh, PA),
1:00pm	Discussions of Research Priorities and Potential Collaborations

2:00pm

Closing Remarks and Lunch To-Go